Aislinn Antrim, Managing Editor

Research reveals a significant link between maternal anemia and increased risk of congenital heart defects in infants, highlighting the need for effective prevention strategies.

New trial results highlight intravenous immunoglobulin (IVIG) 10% as an effective rescue treatment for relapsing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), enhancing patient care and pharmacist involvement in management.

The American Lung Association is raising awareness about updated pneumococcal vaccine guidelines, emphasizing prevention and patient education for at-risk populations.

Experts provide guidance on managing high cholesterol in adults older than 75 years, emphasizing personalized care and shared decision-making for optimal outcomes.

Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

New research reveals how high blood sugar from type 2 diabetes alters brain function, mimicking early Alzheimer symptoms and impacting memory.

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan.

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discusses concerns about the implementation of the MDPNP.

These data provide compelling evidence to revise existing transfusion protocols, recommending 4F-PCC as the preferred treatment for hemostatic management in cardiac surgery.

Data show that the system is also the most accurate continuous glucose monitor (CGM).

Host Craig Beavers speaks with Steven Dunn about the latest ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

Similar legislation could also address PBM practices in commercial insurance.

Host Craig Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.

The Protecting Pharmacies in Medicaid Act aims to tackle spread pricing, but other legislation could target different issues.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

The availability of this option could make physicians more comfortable when prescribing ticagrelor, which could help solve the challenge of undertreatment with antiplatelet therapy.

Rivaroxaban offers more predictable dosing, eliminates frequent blood tests, and is less likely to interact with foods.

The results should lead to a guideline update recommending extended treatment with a reduced-dose anticoagulant in this patient population.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.

Kaite Krell, MPH, discusses the critical role of independent pharmacies and how proposed legislation could address challenges with PBMs.

Optimal glycemic control and medication delivery rely upon proper tools and techniques.

The legislation is expected to improve the financial stability of independent and community pharmacies by ensuring fair reimbursement rates and allowing them to better manage their finances.

Matthew Zirwas, MD, highlights the discrepancy between perceived and actual usage, citing studies that reveal patients often overestimate their compliance.

Although dietary changes have historically been a key approach to managing eosinophilic esophagitis, their limitations highlight the need for pharmacologic treatments.

Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs.

Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo.